For the use only of a Registered Veterinary Practitioner or a Hospital or a Laboratory or a Farm.

In management of **Congestive Heart Failure** in dogs.

Pimobendan 1.25 mg / 2.5 mg / 5 mg / 10 mg Tablets

PETMEDIN™ 1.25/2.5/5/10

Yum-Tab!

COMPOSITION:
Each uncoated tablet contains:
Pimobendan Ph.Eur ..... 1.25 mg / 2.5 mg / 5 mg / 10 mg
Excipients.....q.s.

CATEGORY: Inodilator (calcium sensitizer and phosphodiesterase III inhibitor)

DESCRIPTION:
Pimobendan, a benzimadazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties.

INDICATIONS:
Petmedin Tablets are indicated for

- The treatment of canine congestive heart failure (CHF) originating from dilated cardiomyopathy (DCM) or valvular insufficiency (mitral and/or tricuspid valve regurgitation).
- The treatment of preclinical DCM in large breed dogs. When used in cases of preclinical DCM in large breed dogs, pimobendan significantly prolonged the time to the onset of CHF or sudden death, and also resulted in prolongation of the time to death due to all causes.
- Doberman Pinscher dogs with preclinical DCM treated with pimobendan also demonstrated a significant reduction in Left Ventricular Internal Diameter in both systole and diastole (LVIDs/d) in response to therapy.
- The treatment of dogs with evidence of increased heart size secondary to asymptomatic (preclinical) myxomatous mitral valve disease to delay the onset of clinical symptoms of heart failure, to reduce heart size and to increase survival time.

DOSAGE AND ADMINISTRATION:
The dose rate of Pimobendan is 0.5mg/kg body weight.

The dose should be 0.25 mg/kg body weight twice daily, one half of the dose in the morning and the other half approximately 12 hours later. Each dose should be given on an empty stomach and atleast one hour before feeding.

Body Weight (kg)	No. of tablets per administration							
	Morning / Evening							
	1.25 mg	2.5mg	5 mg			10mg		
2 – 5	½	-						
> 5 – 10	1	-				-		
> 10 – 20	-	1	or	½		-		
> 20 – 40	-	-	1	or	½			
> 40 – 60	-	-	2	or	1			
> 60 – 80	-	-	3	or	1½			
> 80	-	-	4	or	2			

The product may be combined with a diuretic treatment such as furosemide
Or as directed by the Veterinarian.

Administration:
Oral

TARGET SPECIES:
Dogs

PHARMACODYNAMIC PROPERTIES:
Pharmacotherapeutic group: Cardiac stimulant (phosphodiesterase III inhibitor)
ATCvet code: QC01CE90

PHARMACODYNAMICS:
Pimobendan exerts its stimulatory myocardial effect by a dual mechanism of action: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (type III). It also exhibits a vasodilating action through an inhibitory action on phosphodiesterase III activity.

PHARMACOKINETICS:
Absorption:
Following oral administration of pimobendan, the absolute bioavailability of the active principle is 60 - 63%. Since this bioavailability is considerably reduced when pimobendan is administered with food or shortly thereafter, it is recommended to treat animals approximately 1 hour before feeding.

Distribution:
The volume of distribution is 2.6 l/kg, indicating that pimobendan is distributed readily into the tissues. The mean plasma protein binding is 93 %.

Metabolism:
The compound is oxidatively demethylated to its major active metabolite (UD-CG 212). Further metabolic pathways are phase II conjugates of UD-CG 212, in essence glucuronides and sulfates.

Elimination:
The plasma elimination half-life of pimobendan is approximately 30 minutes and the main active metabolite elimination half-life is approximately 2 hours. Almost the entire dose is eliminated via faeces.

WARNING & PRECAUTION :

- Do not exceed the recommended dosage.
- Determine the bodyweight accurately before treatment to ensure correct dosage.
- This product should be used only in dogs with cardiac insufficiency.
- In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Accidental ingestion, especially by a child, may lead to the occurrence of tachycardia, orthostatic hypotension, flushing of the face and headaches.

CONTRAINDICATIONS:
The product should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis).

Do not administer to animals other than those for which it is indicated.

Hypersensitivity to any of the Ingredients.

PREGNANCY AND LACTATION:
The safety of the product has not been assessed in pregnant or nursing bitches. Use only if the expected therapeutic benefits overweigh the potential risk assessment by the responsible veterinarian.

DRUG INTERACTIONS:
In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. The pimobendan induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the ß-antagonist propranolol.

ADVERSE EFFECTS:
A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and can be avoided by reducing the dose in those cases.

In rare cases transient diarrhoea, anorexia or lethargy have been observed.

OVERDOSAGE:
In the case of overdose, a positive chronotropic effect and vomiting may occur. In this situation, the dosage should be reduced and appropriate symptomatic treatment should be initiated.

STORAGE:
Store below 30°C in a dry place.

PRESENTATION:
3 Blisters containing 10 Tablets each is packed in a Carton along with the Pack Insert.

FOR ANIMAL TREATMENT ONLY
NOT FOR HUMAN USE

KEEP OUT OF REACH OF CHILDREN & PETS, AWAY FROM FOOD.

Carefully read the accompanying instructions before use.

Vekö

Manufactured & Marketed by:
Veko Care Pvt. Ltd.
Plot No. E-48 & 49, MIDC, Ranjangaon, Dist-Pune.
Maharashtra, India. Pin Code: 412220
Customer care: care@vekocare.com
TM : Trademark of Veko Care

VPPIE046